OTHER
Therapeutics
In adolescents with SSRI resistant depression, CBT/combined treatment is most effective in those with comorbid disorders
| The first 150 words of the full text of this article appear below. |
What are the predictors and moderators of treatment response among adolescents with selective serotonin reuptake inhibitor (SSRI) resistant depression?
334 adolescents (aged 12–18 years) with a primary diagnosis of major depressive disorder in active treatment but who had not responded to a 2 month trial with an SSRI. See online notes for main exclusions.
US academic and community clinics; 2000–2006.
One of four 12 week regimens: switch to a second, different SSRI (paroxetine, fluoxetine or citalopram at 20–40 mg daily); switch to venlafaxine (150–225 mg daily); switch to second SSRI plus CBT; switch to venlafaxine plus CBT. Before the switch, participants existing medication was tapered to discontinuation over up to 2 weeks. CBT was delivered by experienced therapists with at least masters level qualifications; up to 12 sessions of CBT (60–90 min each) were provided during the first 12 weeks (3–6 of them were family sessions). Predictor and moderator
University of Cambridge, Cambridge, UK
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
